HORACIO ALONSO GALÁN-rekin lankidetzan egindako argitalpenak (9)

2024

  1. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

    American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

2022

  1. Local genetic variation of inflammatory bowel disease in Basque population and its effect in risk prediction

    Scientific Reports, Vol. 12, Núm. 1

  2. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2020

  1. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 89-98

  2. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)

    Helicobacter, Vol. 25, Núm. 3

2019

  1. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies

    Helicobacter, Vol. 24, Núm. 1

2017

  1. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance

    World Journal of Gastroenterology, Vol. 23, Núm. 18, pp. 3367-3373

2016

  1. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance

    Helicobacter, Vol. 21, Núm. 1, pp. 29-34